SMS Pharmaceuticals is currently trading at Rs. 38.15, up by 1.20 points or 3.25% from its previous closing of Rs. 36.95 on the BSE.
The scrip opened at Rs. 38.50 and has touched a high and low of Rs. 41.75 and Rs. 38.15 respectively. So far 3477 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 69.10 on 11-Mar-2019 and a 52 week low of Rs. 35.60 on 28-Feb-2020.
Last one week high and low of the scrip stood at Rs. 41.75 and Rs. 36.00 respectively. The current market cap of the company is Rs. 330.14 crore.
The promoters holding in the company stood at 67.29%, while Institutions and Non-Institutions held 0.5 % and 32.16% respectively.
The United States Food and Drug Administration (USFDA) has successful completed regulatory inspection at SMS Pharmaceuticals’ exclusive testing facility during March 02, 2020 to March 06, 2020. The regulatory audit resulted in zero observation.
The company is committed to meeting the highest quality standards and is further committed to full compliance with CGMP & GLP regulations at all its manufacturing & Analytical facilities. The 'Central Laboratory Analytical Services' is company’s independent testing laboratory, and this was the first USFDA inspection concluded with zero observations.
SMS Pharmaceuticals is a global player in API manufacturing having strong research and manufacturing team supported by state of art facilities.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: